Previous 10 | Next 10 |
– US government contracts for approximately $1 billion 1 (USD) now in place to purchase sotrovimab, further expanding access nationwide – – This brings the total number of doses secured through binding agreements to more than 750,000 globa...
Established COVID-19 vaccine makers have come under pressure after Pfizer (NYSE:PFE) and a United Nations-backed public health organization announced a licensing pact to allow generic-drugmakers to produce cheaper versions of the company’s experimental COVID-19 pill. Moderna (NASD...
– New data from ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate notable reductions in HBsAg and support their positive safety profiles – SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) to...
– COMET-TAIL Phase 3 data demonstrated that intramuscular administration of sotrovimab was non-inferior and offered similar efficacy to intravenous administration for high-risk populations – – The trial enrolled participants during the Delta varian...
Vaccine-focused biotech stocks have been amazing performers over the last couple of years -- particularly if you owned the right ones. Novavax (NASDAQ: NVAX) jumped from a micro-cap to a $12 billion valuation. And of course, mRNA vaccine specialists have been on fire. Moderna ...
The emerging dominance of COVID-19 pills and concerning outlook for vaccine makers dominated healthcare headlines this week amid a flurry of earnings reports. Yet, with an over twofold rise in value, a clinical-stage Alzheimer’s drug developer outshone them all. However, pressure on va...
Shares of Vir Biotechnology (NASDAQ: VIR) are under pressure after the company's third-quarter earnings report. Investors unimpressed with the biotech's progress selling a COVID-19 treatment pushed the stock 14.9% lower as of 2:18 p.m. on Friday. Vir Biotechnology reported signi...
Established makers of COVID-19 antibody treatments Vir Biotechnology (VIR -14.7%), Regeneron (REGN -6.1%), and Eli Lilly (LLY -2.8%) have become the latest additions to a selloff driven by positive data from Pfizer (PFE +8.1%) for its experimental COVID-19 pill. Despite the selloff in ma...
Vir Biotechnology (NASDAQ:VIR): Q3 GAAP EPS of $0.82 beats by $0.74. Revenue of $103.6M (+5267.9% Y/Y) misses by $34.65M. Press Release As of September 30, 2021, excluding restricted cash, the Company had approximately $939.5M in cash, cash equivalents and investments. Excluding restricted ca...
– To date, binding sales agreements for more than 420,000 doses of sotrovimab secured worldwide – – In the third quarter, well over 50,000 doses delivered and $102.4M of sotrovimab collaboration revenue recognized – – Anticipated fourth quarter m...
News, Short Squeeze, Breakout and More Instantly...
Vir Biotechnology Inc. Company Name:
VIR Stock Symbol:
NASDAQ Market:
Vir Biotechnology Inc. Website:
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024. Financial results will ...
2024-07-11 12:00:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the second of a two-part series looking at recent news and developments in the blood infections treatment market, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:C...
2024-07-08 10:47:03 ET BITX (BITX) BITX is trading DOWN for the last 4 days, and it at trading at $27.48 with volume of 3,908,355 and a one day change of $-0.37 (-1.33%). BITX has a 52-week low of 0.00 and a 52-week high of $0.00. The business's 50-day moving average price is $45.40...